Suggested remit: To appraise the clinical and cost effectiveness of low-dose atropine eye drops within its marketing authorisation for treating myopia in people 3 to 14 years.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- Scoping commenced.
- Process:
- STA Standard
- ID number:
- 6517
Provisional Schedule
- Committee meeting: 1:
- 08 July 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Santen (low-dose atropine eye drops [Ryjunea])
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Eyecare Trust
- Fight for Sight
- Macular Society
- Myopia Focus
- National Federation of the Blind of the UK
- Royal National Institute of Blind People (RNIB)
- SeeAbility
- Sense
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Thomas Pocklington Trust
- Professional groups
- Association of Optometrists
- British & Irish Paediatric Ophthalmology and Strabismus Association
- British and Irish Orthoptic Society
- British Ophthalmic Anaesthesia Society
- College of Optometrists
- Myopia Consortium UK
- Neonatal and Paediatric Pharmacy Group
- Optical Confederation
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Ophthalmologists
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Eyes and Vision Group
- Eye Hope
- Genomics England
- Institute of Ophthalmology, University College London
- Moorfields Eye Charity
- MRC Clinical Trials Unit
- National Institute for Health Research
- Sight Research UK
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 November 2025 | Invitation to participate |
| 16 June 2025 | The NICE Prioritisation Board (PB) met on Monday 16 June 2025 to consider the findings of the scoping exercise for this topic. PB subsequently agreed that low-dose atropine eye drops for treating myopia in people 3 to 14 years, should be selected for evaluation and ministerial referral from the Department of Health and Social Care (DHSC) will now be sought |
| 24 March 2025 - 23 April 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6517 |
| 24 March 2025 | In progress |
| 12 December 2024 | Awaiting development |
| 12 December 2024 | Topic selection. . |
For further information on our processes and methods, please see our CHTE processes and methods manual